Laurie Letvak
Overview
Explore the profile of Laurie Letvak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heidel F, Cortes J, Rucker F, Aulitzky W, Letvak L, Kindler T, et al.
Cancer
. 2007 Feb;
109(5):907-14.
PMID: 17285599
Background: Imatinib (IM) is a potent tyrosine kinase inhibitor of c-Kit. c-Kit is expressed in the majority of patients with acute myeloid leukemia (AML). Whereas clinical trials evaluating monotherapy with...
2.
Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N, et al.
N Engl J Med
. 2006 Dec;
355(23):2408-17.
PMID: 17151364
Background: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus...
3.
Wen P, Yung W, Lamborn K, Dahia P, Wang Y, Peng B, et al.
Clin Cancer Res
. 2006 Aug;
12(16):4899-907.
PMID: 16914578
Purpose: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs (EIAED) or not taking EIAED....
4.
Owen S, Hatfield A, Letvak L
N Engl J Med
. 2006 Aug;
355(6):627.
PMID: 16899786
No abstract available.
5.
Kantarjian H, Talpaz M, OBrien S, Garcia-Manero G, Verstovsek S, Giles F, et al.
Blood
. 2004 Apr;
103(8):2873-8.
PMID: 15070658
Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated...
6.
Thomas D, Faderl S, Cortes J, OBrien S, Giles F, Kornblau S, et al.
Blood
. 2003 Oct;
103(12):4396-407.
PMID: 14551133
Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in refractory/relapsed Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL). Use of concurrent chemotherapy and imatinib mesylate in newly...
7.
Cortes J, Giles F, OBrien S, Thomas D, Albitar M, Rios M, et al.
Cancer
. 2003 May;
97(11):2760-6.
PMID: 12767088
Background: Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R). c-kit is expressed in most patients with acute myeloid leukemia (AML) and...
8.
Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, et al.
Blood
. 2003 Feb;
101(12):4714-6.
PMID: 12595304
Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia and organ involvement. Different treatments have been investigated in HES with modest success. It has been suggested that...
9.
Kantarjian H, Cortes J, OBrien S, Giles F, Garcia-Manero G, Faderl S, et al.
Blood
. 2002 Oct;
101(1):97-100.
PMID: 12393600
Fifty patients with Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median follow-up of 9 months, 49 patients...